Insider Selling: Steven R. Hagen Sells 1,250 Shares of Albany Molecular Research Stock (AMRI)
Albany Molecular Research (NASDAQ:AMRI) SVP Steven R. Hagen sold 1,250 shares of the stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $19.74, for a total value of $24,675.00. Following the completion of the transaction, the senior vice president now directly owns 30,933 shares in the company, valued at approximately $610,617. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of Albany Molecular Research from an “outperform” rating to a “neutral” rating in a research note on Tuesday, August 12th. They now have a $23.70 price target on the stock. Separately, analysts at Morgan Stanley reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00. Finally, analysts at Sterne Agee reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00.
Shares of Albany Molecular Research (NASDAQ:AMRI) traded down 2.47% on Tuesday, hitting $19.31. The stock had a trading volume of 534,928 shares. Albany Molecular Research has a one year low of $9.71 and a one year high of $22.30. The stock has a 50-day moving average of $19.72 and a 200-day moving average of $17.89. The company has a market cap of $609.3 million and a P/E ratio of 39.76.
Albany Molecular Research (NASDAQ:AMRI) last released its earnings data on Tuesday, August 5th. The company reported $0.22 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.20 by $0.02. The company had revenue of $68.20 million for the quarter, compared to the consensus estimate of $65.64 million. Analysts expect that Albany Molecular Research will post $0.91 EPS for the current fiscal year.
Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.
Receive News & Ratings for Albany Molecular Research Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.